First Parkinson’s Patient Dosed in Early Trial of DNL151, Potential LRRK2 Inhibitor
A Phase 1b clinical trial exploring the oral LRRK2 inhibitor DNL151 has started dosing Parkinson’s patients, the therapy’s developer…
Articles by José Lopes, PhD
Engineered Protein Binds to Alpha-synuclein to Prevent Toxic Clumping, Study Reports
An engineered protein known as AS69 is able to bind to individual units of alpha-synuclein to prevent them from clumping,…
Floors with Distinct Patterns May Ease Freezing of Gait in Parkinson’s Patients, Study Reports
Floor patterns with large, transverse visual cues may lessen freezing of gait in patients with Parkinson’s, according to…
Phase 2b/3 Trial Testing IRLAB’s IRL790 in Levodopa-induced Dyskinesia to Start in 2020
Following the positive results of a Phase 2a clinical trial, IRLAB Therapeutics is planning a Phase 2b/3 study for…
Phase 2 Trial of Parkinson’s Psychosis Therapy Enrolling Across U.S.
A Phase 2 clinical trial of SEP-363856, an oral treatment candidate for patients with Parkinson’s psychosis, is recruiting…
Depression Is Risk Factor for Impulse Control Disorders in Parkinson’s Patients, Study Finds
Patients with Parkinson’s are at a greater risk of developing impulse control disorders (ICDs) if they are depressed, according…
Protein Clumping Best Blocked Using Specific Compounds at Distinct Disease Stages, Model Suggests
A mathematical model created to more effectively prevent protein clumping, widely thought to underlie diseases like Parkinson’s, found that different…
Deep Brain Stimulation Eases Parkinson’s Symptoms by Directly Raising Dopamine Levels, Study Suggests
Deep brain stimulation (DBS) eases tremors and muscle rigidity, and improves cognition and mood in Parkinson’s patients by raising…
Treatment with Stalevo and Comtan Does Not Raise Prostate Cancer Risk, FDA Finds
A review by the U.S. Food and Drug Administration (FDA) found that Parkinson’s patients treated with medications containing entacapone are at…
With BlueRock Acquisition, Bayer Plans to Open Trial of Cell Therapy for Parkinson’s
Bayer has announced an agreement to acquire the cell therapy company BlueRock Therapeutics, and plans to open…